Orum Therapeutics Past Earnings Performance
Past criteria checks 4/6
Orum Therapeutics has been growing earnings at an average annual rate of 183.2%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 54.2% per year. Orum Therapeutics's return on equity is 75.9%, and it has net margins of 63.6%.
Key information
183.2%
Earnings growth rate
29.1%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 54.2% |
| Return on equity | 75.9% |
| Net Margin | 63.6% |
| Next Earnings Update | 25 Mar 2025 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Orum Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 156,210 | 99,290 | 17,306 | 17,373 |
| 30 Jun 24 | 135,357 | 75,595 | 17,593 | 16,527 |
| 31 Mar 24 | 135,388 | 71,906 | 18,323 | 17,617 |
| 31 Dec 23 | 135,418 | 68,217 | 19,054 | 18,706 |
| 31 Dec 22 | 76 | -63,319 | 9,083 | 33,168 |
Quality Earnings: A475830 has high quality earnings.
Growing Profit Margin: A475830's current net profit margins (63.6%) are higher than last year (34.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A475830's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare A475830's past year earnings growth to its 5-year average.
Earnings vs Industry: A475830 earnings growth over the past year (183.2%) exceeded the Biotechs industry 22.3%.
Return on Equity
High ROE: A475830's Return on Equity (75.9%) is considered outstanding.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 09:33 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orum Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.